Delphine Diagnostics

Andy Bala

Founder & CEO -



Problem- Sepsis, a Silent Killer

 # 1
Cause of deaths
in US Hospitals

350,000
Deaths year in US
11,000,000
Worldwide

80%
Deaths are preventable

8%
Increase in mortality for every hour of delay

Source: US CDC

Solution - Delphine's Dual Approach

Sepsis Test kit

- **6 times faster than standard of care**





ML Prediction software tool

- **Predicts sepsis several hours before onset**
- Cuts down re-admission rate by 5%



Competitive Landscape: Sepsis Test Kit, ML Model(CDSA)





Market Opportunity

$ 75 B


Market opportunity in USA

$ 17.8 B

Serviceable addressable market

$ 2.8 B

Serviceable obtainable market



Business Model, B2B Sales with Strategic Entry Points

Customers	Physicians at ER/ICUs, Lab Directors
Sales model	IDNs, Direct and Channel Partners
Advantage w/ GTM Strategy	Product launch via RUO and LDT – no FDA delays

Legend

RUO: Research Use Only, and LDT: Lab Developed Tests,
IDN: Integrated Delivery Networks

Early Traction

Design partnership agreements(2) with Cooper Health System(USA), and AIIMS(India)

Pipeline: (6) (four hospitals, two reference labs) – NDA signed

Won Competitive Grant: M& IH R & D Innovation grant from New Jersey State Government –
NJ CSIT March 2025

Legend: *M & IH: Maternal and Infant Health*
NJ CSIT: New Jersey Commission on Science Technology and Innovation

Industry Experienced, Passionate Mission-Driven Team

Core Team



Andy Bala

Founder & CEO
B.E (Hons.), M.Tech, M.B.A



Vidhya Gopalkrishnan

PhD, CPO



Michael Raimondo

B.S **Advisor-Commercialization Head**

ADVISORS



Steven Q. Simpson

MD Chairman – Clinical Advisory Board



Raj Devalapalli

MS MBA – Senior Strategy Advisor



Monica C Smith

B.A, Advisor – Marketing

Raising $2M Pre-Seed

a)SAFE note w/ Angel Tax Credit (35%) and 15% discount (negotiable)


b) Outcome(s) from Funding:

R&D completion
FDA submission and
Early revenue(RUO and LDT)

Why invest Now?

- **We're in an AI gold rush:** in just two years, propelled AI from theory into production-ready reality-
- let's seize the moment.

Use of Funds



Save lives and Prevent disabilities

A purpose driven journey

- 350,000 Deaths/year in the US

At Delphine, we focus on AI that matters:

No one should die from a treatable infection. Join us. Thank you.



Delphine Diagnostics Inc

Profeta innovation center 211 warren street, Newark, NJ 07103

Tel: +1 (862)-235-4883

abala@delphinedx.com